Samil Pharmaceutical KRX:000520KOSPI
삼일제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Samil Pharmaceutical reported revenue of ₩50.6bn, down 5.9% year on year, and an operating loss of ₩6.3bn. Samil Pharmaceutical (삼일제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
Samil Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩50.6bn | -5.9% | −₩6.3bn | −₩7.7bn |
| Q1 2026 | ₩52.5bn | +0.5% | −₩8.4bn | −₩10.8bn |
| Q4 2025 derived | ₩53.0bn | -8.3% | −₩8.6bn | −₩11.2bn |
| Q3 2025 | ₩51.2bn | -4.0% | −₩5.2bn | −₩7.9bn |
| Q2 2025 | ₩53.8bn | -0.9% | −₩3.1bn | −₩6.5bn |
| Q1 2025 | ₩52.3bn | -3.7% | −₩5.4bn | −₩9.1bn |
| Q4 2024 derived | ₩57.8bn | +14.4% | −₩2.9bn | −₩3.6bn |
| Q3 2024 | ₩53.3bn | +3.3% | −₩240m | −₩676m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Samil Pharmaceutical top stories 2 weeks, by number of outlets
- 1